Exchange: AMEX Sector: Healthcare Industry: Biotechnology
9.63% $2.05
America/New_York / 2 mai 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 33.08 mill |
EPS: | -2.98 |
P/E: | -0.690 |
Earnings Date: | May 14, 2024 |
SharesOutstanding: | 16.14 mill |
Avg Daily Volume: | 0.643 mill |
RATING 2024-05-02 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.690 | sector: PE -4.07 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -0.690 | industry: PE -5.55 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.517 (-74.76%) $-1.533 |
Date: 2024-05-02 |
Expected Trading Range (DAY) |
---|
$ 1.784 - 2.32 ( +/- 12.98%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-11 | Deveer Robert K Jr | Buy | 6 000 | Common Stock |
2024-03-06 | Deveer Robert K Jr | Sell | 1 685 | Common Stock |
2024-03-06 | Deveer Robert K Jr | Sell | 7 286 | Common Stock |
2024-03-06 | Deveer Robert K Jr | Sell | 200 | Common Stock |
2024-03-06 | Deveer Robert K Jr | Sell | 1 808 | Common Stock |
INSIDER POWER |
---|
47.32 |
Last 100 transactions |
Buy: 594 391 | Sell: 320 931 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.05 (9.63% ) |
Volume | 0.644 mill |
Avg. Vol. | 0.643 mill |
% of Avg. Vol | 100.25 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.